Prosthesis Survival
Conditions
Keywords
disease free survival, overall survival
Brief summary
This phase II clinical trial was designed to assess the feasibility, safety, toxicity, recurrence and survival pattern when TP or CAP chemotherapy was combined with adjuvant radiation for patients with high-risk endometrial cancer.
Interventions
RADIATIONradiotherapy
Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
DRUGCisplatin
Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
DRUGCisplatin and Doxorubicin and Cyclophosphamide
Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
Sponsors
Fan Ming
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients must have had a hysterectomy (total abdominal, vaginal hysterectomy, or laparoscopic-assisted vaginal hysterectomy) or modified radical hysterectomy or radical hysterectomy and bilateral salpingo-oophorectomy no more than 8 weeks prior to start of radiation therapy. Additional surgical staging procedures are permissible but not required. * Risk factors: patients must fit one of the following: * Pelvic lymph node metastases * Paraaortic lymph node metastases * Grade 3 with myometrial invasion \>50% * With stromal invasion of cervix * Known extrauterine disease (excluding second primary) confined to the pelvis. * High risk pathological type include: uterine papillary serous carcinoma, clear cell carcinoma, squamous cell carcinoma, undifferentiated carcinoma, * No known gross residual disease, or distant metastases. * Eastern Cooperative Oncology Group (ECOG) score\<=2; Age 18\ 75. * White Blood Cell (WBC)≥4000/mm3, granulocytes ≥1500/mcl, platelets≥100,000/mcl. * Acceptable hepatic and renal function: creatinine \<=1.4 mg%, bilirubin and serum glutamate oxaloacetate transaminase (SGOT) \<=2\*normal. * No medical contraindications to chemotherapy, or radiation therapy. * Study-specific signed informed consent.
Exclusion criteria
* Prior pelvic radiation therapy. * Positive peritoneal cytology only for stage IIIa (FIGO 1998). * With history of other malignancies less than 5 years. * With gross residual disease, or distant metastases. * With endometrioid endometrial carcinoma and no risk factors: * with myometrial invasion \<50% * Grade 1\ 2, with myometrial invasion \>50% * With serious internal diseases which affect designed treatment * With psychotic disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease Free Survival(DFS) | From date of randomization until the date of first documented progression, assedded up to 60 months | From date of randomization until the date of first documented progression, assessed up to 60 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From date of randomization until the date of death from any cause, assedded up to 60 months. | From date of randomization until the date of death from any cause, assessed up to 60 months. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with adverse events and number of patients completed the treatments | up to 5 years | Number of patients completed the treatment and number of patients with adverse events up to 5 years. |
Countries
China
Outcome results
None listed